구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | DOAC (Direct Oral Anticoagulant, Direct Oral Anticoagulant (DOAC)) Janssen Research & Development, LL…·Carcinoma, Non-small-Cell Lung 133 trials |
|---|---|
Overview Program | Direct Oral Anticoagulant (DOAC) |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Non-small-Cell Lung |
Overview Indication | Carcinoma, Non-small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | of DOACs targeting thrombin or FXa on the metastasis of murine melanoma B16 cells implanted in mice |
MoA Biomarker | biomarker co-primary trials, not extension of indications |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy.. Concomitant use of antiseizure medications (ASMs) and direct oral anticoagulants (DOACs) is common in epilepsy, but comparative safety data remain limited. To compare risks of thromboembolic events, major bleeding, and all-cause mortality across commonly used ASMs in adults with epilepsy receiving DOACs. This … |
Clinical Safety signal | Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy.. Concomitant use of antiseizure medications (ASMs) and direct oral anticoagulants (DOACs) is common in epilepsy, but comparative safety data remain limited. To compare risks of thromboembolic events, major bleeding, and all-cause mortality across commonly used ASMs in adults with epilepsy receiving DOACs. This … |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | DOAC (Direct Oral Anticoagulant, Direct Oral Anticoagulant (DOAC)) Janssen Research & Development, LL…·Carcinoma, Non-small-Cell Lung 133 trials |
|---|---|
Overview Program | Direct Oral Anticoagulant (DOAC) |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Non-small-Cell Lung |
Overview Indication | Carcinoma, Non-small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | of DOACs targeting thrombin or FXa on the metastasis of murine melanoma B16 cells implanted in mice |
MoA Biomarker | biomarker co-primary trials, not extension of indications |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy.. Concomitant use of antiseizure medications (ASMs) and direct oral anticoagulants (DOACs) is common in epilepsy, but comparative safety data remain limited. To compare risks of thromboembolic events, major bleeding, and all-cause mortality across commonly used ASMs in adults with epilepsy receiving DOACs. This … |
Clinical Safety signal | Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy.. Concomitant use of antiseizure medications (ASMs) and direct oral anticoagulants (DOACs) is common in epilepsy, but comparative safety data remain limited. To compare risks of thromboembolic events, major bleeding, and all-cause mortality across commonly used ASMs in adults with epilepsy receiving DOACs. This … |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교